Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines

NCT05507671 is registered in ClinicalTrials.gov with Oswaldo Cruz Foundation as lead sponsor.

NCT NCT05507671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines
Lead sponsor
Oswaldo Cruz Foundation
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 27, 2021
Completion date
December 31, 2025
Enrollment
556 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19